February 1, 2023 01:05 PM ESTUpdated 02:14 PM
Pharma
FDA+

Pfiz­er brings Ibrance to new sub­set of breast can­cer pa­tients, re­gard­less of menopausal sta­tus

Nicole DeFeudis

Editor

Pfiz­er has ex­pand­ed Ibrance’s use to in­clude a new sub­set of breast can­cer pa­tients, the com­pa­ny slipped in­to its quar­ter­ly earn­ings re­port on Tues­day. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times